Efficient Production of \((R)-2\)-Hydroxy-4-Phenylbutyric Acid by Using a Coupled Reconstructed \(\alpha\)-Lactate Dehydrogenase and Formate Dehydrogenase System

Binbin Sheng\(^1\), Zhaojuan Zheng\(^2\), Min Lv\(^1\), Haiwei Zhang\(^1\), Tong Qin\(^1\), Chao Gao\(^*\), Cuqing Ma\(^1\), Ping Xu\(^1\)

\(^1\)State Key Laboratory of Microbial Technology, Shandong University, Jinan, People’s Republic of China, \(^2\)College of Chemical Engineering, Nanjing Forestry University, Nanjing, People’s Republic of China

Abstract

**Background:** \((R)-2\)-Hydroxy-4-phenylbutyric acid \([(R)-HPBA]\) is a key precursor for the production of angiotensin-converting enzyme inhibitors. However, the product yield and concentration of reported \((R)-HPBA\) synthetic processes remain unsatisfactory.

**Methodology/Principal Findings:** The Y52L/F299Y mutant of NAD-dependent \(\alpha\)-lactate dehydrogenase \((\alpha-nLDH)\) in *Lactobacillus bulgaricus* ATCC 11842 was found to have high bio-reduction activity toward 2-oxo-4-phenylbutyric acid \((\text{OPBA})\). The mutant \(\alpha-nLDH\) was then coexpressed with formate dehydrogenase in *Escherichia coli* BL21 (DE3) to construct a novel biocatalyst *E. coli* DF. Thus, a novel bio-reduction process utilizing whole cells of *E. coli* DF as the biocatalyst and formate as the co-substrate for cofactor regeneration was developed for the production of \((R)-HPBA\) from OPBA. The biocatalysis conditions were then optimized.

**Conclusions/Significance:** Under the optimum conditions, 73.4 mM OPBA was reduced to 71.8 mM \((R)-HPBA\) in 90 min. Given its high product enantiomeric excess (\(>99\%\)) and productivity (47.9 mM h\(^{-1}\)), the constructed coupling biocatalysis system is a promising alternative for \((R)-HPBA\) production.

Introduction

\((R)-2\)-hydroxy-4-phenylbutyric acid \([(R)-HPBA]\) and ethyl \((R)-2\)-hydroxy-4-phenylbutyrate \([(R)-HPBE]\) can be used as the key precursors for the production of angiotensin-converting enzyme \((ACE)\) inhibitors \([1–5]\). ACE inhibitors such as benazepril, enalapril, lisinopril, ramipril, and quinapril are widely used in the first-line therapy of hypertension and congestive heart failure \([6–9]\). Owing to the substantial demand for these drugs, various chemical or biological processes have been developed to produce \((R)-HPBA\) or \((R)-HPBE\). In recent years, great success has been achieved in asymmetric synthesis of \((R)-HPBE\) catalyzed by recombinant reductases \([10,11]\). For example, whole cells of a recombinant *Escherichia coli* strain harboring CgKR2 and glucose dehydrogenase \((\text{GDH})\) were applied in preparing \((R)-HPBE\) with high concentration, desirable enantiomeric excess \((\text{ee})\) \((>99\%)\) and yield \([10]\). Compared with that of \((R)-HPBE\), the product yield and concentration of the reported \((R)-HPBA\) synthesis processes remained unsatisfactory \([1,12]\).

In previous studies, enzymatic resolution and asymmetric reduction were used in the biological production of \((R)-HPBA\). Compared with enzymatic resolution catalyzed by hydrolases, especially lipases \([4,9,13]\), asymmetric bio-reduction of 2-oxo-4-phenylbutyric acid \((\text{OPBA})\) by dehydrogenases is more desirable because of its excellent stereoselectivity and high theoretical yield up to 100\% \([1,14]\). For practical production of \((R)-HPBA\) from OPBA through bio-reduction, highly efficient reductases and cofactor regeneration systems are needed.

In contrast to the \((R)-HPBE\) preparation processes, which often utilize a specific carbonyl reductase, the production of \((R)-HPBA\) from OPBA is catalyzed by 2-ketocid reductases, especially NAD-dependent \(\alpha\)-lactate dehydrogenase \((\alpha-nLDH)\) \([12,15]\). However, as an unnatural substrate of \(\alpha-nLDH\), OPBA could not be efficiently catalyzed by the biocatalyst because of its large aromatic...
Figure 1. Scheme for (R)-HPBA production from OPBA by using a coupled system of reconstructed d-nLDH and FDH.

doi:10.1371/journal.pone.0104204.g001

Microorganisms and growth conditions

The bacterial strains, plasmids, and oligonucleotide primers used in this study are listed in Table 1. E. coli DH5α and BL21 (DE3) were used for general cloning and expression procedures, respectively. E. coli WD, E. coli D1, and E. coli D2 were used to express wild d-nLDH, d-nLDH\(^{Y52L/F299Y}\), and d-nLDH\(^{Y52L/F299Y}\), respectively [14]. E. coli PD containing the vector pETDuet-1 was used as a control. The plasmid pETDuet-ldhD\(^{Y52L/F299Y}\)fdh was constructed as follows: the ldhD\(^{Y52L/F299Y}\) gene was amplified using primers D.f and D.r with plasmid pETDuet-ldhD\(^{Y52L/F299Y}\) as a template. The fdh gene was amplified using primers F.f and F.r with genomic DNA of C. boidiniiNCYC 1513 as a template. The resulting PCR products ldhD\(^{Y52L/F299Y}\) and fdh were digested with Ncol-BamHI and Ndel-XhoI, respectively, and cloned into MCS1 and MCS2 of pETDuet-1 successively to construct pETDuet-ldhD\(^{Y52L/F299Y}\)-fdh. The plasmid pETDuet-ldhD\(^{Y52L/F299Y}\)-fdh was then transformed into E. coli BL21 (DE3) to construct E. coli DF. All of the E. coli strains were grown in Luria-Bertani (LB) medium, and ampicillin was added at a concentration of 100 μg ml\(^{-1}\) if necessary.

Table 1. Strains, plasmids, and oligonucleotide primers used in this study.

| Strain, plasmid, or primer | Relevant characteristics | Source or reference |
|---------------------------|-------------------------|--------------------|
| **Strain**                |                         |                    |
| E. coli DH5α              | q80 lacZ1M15 ΔlacZYA-argF U169 recA1 endA1 hisD17 supE44, thr-1 | Invitrogen         |
| E. coli BL21(DE3)         | F’ ampT gai dcm lan hisD505 r m         | Novagen            |
| C. boidiniiNCYC 1513      | Wild-type, source of fdh gene |NCYC             |
| E. coli PD                | E. coli BL21(DE3) containing vector pETDuet-1 | This study         |
| E. coli WD                | E. coli BL21(DE3) expressing wild type d-nLDH | [14] |
| E. coli D1                | E. coli BL21(DE3) expressing d-nLDH\(^{Y52L/F299Y}\) | [14] |
| E. coli D2                | E. coli BL21(DE3) expressing d-nLDH\(^{Y52L/F299Y}\) | [14] |
| E. coli DF                | E. coli BL21(DE3) expressing d-nLDH\(^{Y52L/F299Y}\) and FDH | This study |
| **Plasmid**               |                         |                    |
| pETDuet-1                 | Expression vector, Amp′ | Novagen            |
| pETDuet-ldhD\(^{Y52L/F299Y}\) | N-terminal His-tagged ldhD\(^{Y52L/F299Y}\) gene in pETDuet-1 | [14] |
| pETDuet-ldhD\(^{Y52L/F299Y}\)-fdh | Both ldhD\(^{Y52L/F299Y}\) and fdh without His-tag in pETDuet-1 | This study         |
| **Oligonucleotide primer**|                         |                    |
| D.f                      | CCAAGGCTGACTAAAAATTGTGCTAGCGA (Ncol) |                    |
| D.r                      | GGATCCCTGCAGCACTTTAAGAAG (BamHI) |                    |
| F.f                      | CATATAGAGATCATGTTAGTCTTTAATGGTGTTA (Ndel) |                    |
| F.r                      | CTCGAGGATATTTCCCTATGTTTTACCCTTTT (XhoI) |                    |

*NCYC, National Collection of Yeast Cultures.
doi:10.1371/journal.pone.0104204.t001
Biocatalyst preparation

The recombinant strains of *E. coli* PD, *E. coli* WD, *E. coli* D1, *E. coli* D2, and *E. coli* DF were all cultured in LB medium (100 μg ml \(^{-1}\) ampicillin) at 37°C to an optical density of 0.6 at 600 nm. IPTG (1 mM) was then added to induce protein expression, and cultures were grown at 16°C for a further 12 h. Cells were harvested by centrifugation at 6,000 rpm for 10 min, washed twice with 67 mM phosphate buffer solution (pH 7.4), and then subjected to successive biotransformation.

Optimization of biocatalysis conditions

To optimize the biotransformation conditions, 5-ml reaction mixtures were incubated at 37°C and 120 rpm in a 25-ml flask. The pH was adjusted from 5.5 to 8.5. The concentrations of OPBA and formate were 25–175 mM. The concentration of the whole cells was 1–8 g dry cell weight (DCW) l \(^{-1}\). Samples (0.2 ml) were collected periodically and centrifuged at 12,000 rpm. The concentrations of OPBA and (R)-HPBA in the supernatant were analyzed by a high-performance liquid chromatography (HPLC) system (Agilent 1100 series, Hewlett-Packard, USA).

Analytical procedures

Cells of *E. coli* PD, *E. coli* WD, *E. coli* D1, *E. coli* D2, and *E. coli* DF were harvested, suspended in 67 mM phosphate buffer solution (pH 7.4) containing 1 mM PMSF, and then disrupted by sonication (Sonic 500 W; 20 KHz) for 5 min in an ice bath. Thereafter, intact cells and cell debris were removed by centrifugation, and the resultant crude extracts were subjected to successive D-nLDH activity assays. The reduction activities of D-nLDH wild-type and mutants toward OPBA were assayed at 37°C in 1 ml of 50 mM Tris-HCl buffer (pH 7.5) containing 0.2 mM NADH, 10 mM OPBA, and the crude extracts of *E. coli* PD, *E. coli* WD, *E. coli* D1, *E. coli* D2, and *E. coli* DF. The rate of NADH decrease was determined by measuring the absorbance change at 340 nm [14,18,19]. One unit of D-nLDH activity was defined as the amount that catalyzed the oxidation of 1 μmol of NADH per minute. The protein concentration was determined by the Lowry procedure by using bovine serum albumin as the standard [20].

OPBA and (R)-HPBA were measured by HPLC (Agilent 1100 series) equipped with an Agilent Zorbax SB-C18 column (150×4.6 mm, 5 μm) and a variable-wavelength detector at 210 nm. The mobile phase consisted of 1 mM H\(_2\)SO\(_4\) and acetonitrile with a ratio of 85:15 (v/v) at a flow rate of 0.7 ml min \(^{-1}\) at 30°C. Stereoselective assays for (R)-HPBA and

![Figure 2. Feasibility of (R)-HPBA production through cofactor regeneration by reconstructed D-nLDH and FDH. (A) OPBA reduction activities in the crude extract of different *E. coli* strains. (B) Asymmetric reduction of OPBA by whole cells of different *E. coli* strains. For *E. coli* PD, *E. coli* WD, *E. coli* D1, and *E. coli* D2, NADH regeneration was conducted by the direct addition of 50 mM glucose. For *E. coli* DF, formate of 50 mM was added in the reaction broth for NADH regeneration.](https://www.plosone.org/figure/2)

![Figure 3. Optimization of the biocatalysis conditions. (A) pH. (B) Concentration of OPBA. doi:10.1371/journal.pone.0104204.g003](https://www.plosone.org/figure/3)
(S)-HPBA were performed by HPLC analysis by using a chiral column (MCI GEL CRS10W, Japan) and a tunable UV detector at 254 nm. The mobile phase was 2 mM CuSO4 and acetonitrile with a ratio of 85:15 (v/v) at a flow rate of 0.5 ml min\(^{-1}\) and a temperature of 25°C. The ee of (R)-HPBA was defined as \([(\text{R})\text{-HPBA}-(\text{S})\text{-HPBA}]/[(\text{R})\text{-HPBA}+(\text{S})\text{-HPBA}]) \times 100\%.

**Results and Discussion**

**Activity of D-nLDH wild-type and mutants toward OPBA**

To evaluate the possibility of transforming OPBA into (R)-HPBA by D-nLDH, the wild type D-nLDH from *L. bulgaricus* ATCC 11842 and its mutants were overexpressed in *E. coli* BL21 (DE3). Crude extracts of *E. coli* PD, *E. coli* WD, and *E. coli* D1 exhibited rather low OPBA reduction activity (Fig. 2A). The Y52L/F299Y mutant of D-nLDH caused the specific activity of the crude extract of *E. coli* D2 to be 233.2–312.3 fold higher than that in extracts of *E. coli* PD, *E. coli* WD, and *E. coli* D1. These results suggest that the mutant D-nLDH\(^{Y52L/F299Y}\) is rather active toward OPBA and may have the potential to efficiently produce (R)-HPBA from OPBA.

**Feasibility of (R)-HPBA production through the cofactor regeneration system**

Asymmetric reduction of OPBA by whole cells of *E. coli* PD, *E. coli* WD, and *E. coli* D2 was investigated to further explore the potential by using D-nLDH in the synthesis of (R)-HPBA. OPBA at 50 mM was used as the substrate. Whole cells of *E. coli* PD, *E. coli* WD, *E. coli* D1, and *E. coli* D2 at a concentration of 8 g DCW \(^{-1}\) were added to the reaction broth. The reaction was conducted at 37°C for 2 h. Here, NADH was regenerated through the direct addition of 50 mM glucose in the reaction system. Whole cells of *E. coli* D2 exhibited higher (R)-HPBA producing capability than did cells of *E. coli* PD, *E. coli* WD, and *E. coli* D1 (Fig. 2B). However, the (R)-HPBA productivity (3.7 mM h\(^{-1}\)) was still rather low because of the low efficiency of the NADH regeneration system. Additionally, organic acids, including pyruvic acid, lactic acid, and acetic acid, accumulated in the reaction broth (Fig. S1).

FDH is a good choice for NADH regeneration in a biocatalysis system because its substrate, formate, has a low cost and its product, carbon dioxide, is easily separated [21–25]. In this work, FDH was coexpressed with D-nLDH\(^{Y52L/F299Y}\) in *E. coli* DF and the (R)-HPBA production capability of the novel biocatalyst was investigated. Formate (50 mM) was added to the reaction broth for the regeneration of NADH. Although the activity of D-nLDH\(^{Y52L/F299Y}\) in the crude extract of *E. coli* DF was lower than in the extract of *E. coli* D2, whole cells of *E. coli* DF exhibited much higher (R)-HPBA producing capability than other biocatalysts (Fig. 2A and Fig. 2B). (R)-HPBA at 49.0 mM was obtained from 50 mM OPBA. The productivity of (R)-HPBA was 24.5 mM h\(^{-1}\). Thus, whole cells of *E. coli* DF were selected as biocatalysts for (R)-HPBA production in the subsequent experiments.

**Optimization of biocatalysis conditions**

To achieve a higher product concentration, the biocatalytic conditions for (R)-HPBA production from OPBA by using whole cells of *E. coli* DF were optimized. The influence of the reaction pH was determined in reaction mixtures containing 13 g DCW \(^{-1}\) whole cells of *E. coli* DF, 50 mM OPBA, 50 mM sodium formate, and 200 mM phosphate buffer (pH ranging from 5.5 to 8.5). After bioconversion at 37°C for 15 min, the highest (R)-HPBA production was detected at pH 6.5 (Fig. 3A).

**Table 2. Effects of concentration of whole cells on biotransformation.**

| Cell concentration (g DCW l\(^{-1}\)) | 1   | 3   | 5   | 6   | 7   | 8   |
|--------------------------------------|-----|-----|-----|-----|-----|-----|
| Reaction time (min)                  | 285 | 140 | 75  | 55  | 50  | 45  |
| (R)-HPBA concentration (mM)          | 33.0| 61.8| 59.9| 59.4| 60.3| 61.1|
| Productivity\(^{b}\) (mM min\(^{-1}\) g\(^{-1}\) DCW) | 0.116| 0.147| 0.160| 0.180| 0.172| 0.170|

\(^a\)Value is the average value of three separate assays.

\(^b\)Productivity was calculated when the reaction was conducted to approximately 80% of the theoretical yield except for the reaction at 1 g DCW l\(^{-1}\) whole cells.

doi:10.1371/journal.pone.0104204.t002

---

**Figure 4. Time course of highly optically pure (R)-HPBA production from OPBA under optimal conditions.** (A) Biotransformation using whole cells of *E. coli* DF as a biocatalyst and formate for cofactor regeneration. (B) Biotransformation using whole cells of *E. coli* D2 as a biocatalyst and glucose for cofactor regeneration. (■), OPBA; (▲), (R)-HPBA; (●), ee.

doi:10.1371/journal.pone.0104204.g004
Table 3. Comparison of recently reported processes for (R)-HPBA or (R)-HPBE production through bio-reduction.

| Biocatalyst | Product (mM) | Productivity (mM h⁻¹) | ee (%) | Co-substrate | References |
|-------------|--------------|------------------------|--------|--------------|------------|
| Whole cells of Candida boidinii CIOC21 | 20 | 1.7 | 99 | 5% glucose | [27] |
| Whole cells of Bacillus pumilus Phe-c3 | 29.6 | 1.1 | 97.1 | 2% glucose | [28] |
| Whole cells of Candida kru sei SW2026 | 79.5 | 5.0 | 97.4 | 5% glucose | [26] |
| Saccharomyces cerevisiae pretreated with α-phenoacyl chloride | 4.8 | 0.2 | 92 | - | [29] |
| Lyophilized cells of E. coli BL21/ pCgKR 2 and lyophilized GDH powders | 1000 | 140.1 | >99 | 27% glucose | [10] |
| Whole cells of E. coli BL21 coexpressing IolS and GDH | 50 | 3.8 | 99.5 | 3.6% glucose | [31] |
| Whole cells of E. coli BL21 coexpressing IolS and GDH | 1600 | 132.1 | 99.5 | 20% glucose | [11] |
| α-LDH from Staphylococcus epidermidis and FDH from Candida boidinii | 182 | 38.2 | >99.8 | 2.2% ammonium formate | [15] |
| Partially purified α-LDH (EC 1.1.1.28) and whole cells of Candida boidinii ATCC 32591 containing FDH | 56.7 | 49.9 | ND | 0.8% sodium formate | [12] |
| Whole cells of E. coli BL21 coexpressing YaE and GDH* | 100 | 4.2 | 98 | 3.6% glucose | [1] |
| Whole cells of E. coli DF* | 71.8 | 47.9 | >99 | 0.5% sodium formate | This study |

*Substrates were OPBA. Substrates of the other processes were OPBE. ND represents no data.
doi:10.1371/journal.pone.0104204.t003

To determine the effect of the OPBA concentration, reactions with eight different OPBA and sodium formate concentrations (25, 50, 75, 100, 125, 150, and 175 mM) were conducted at pH 6.5 and 37°C for 30 min. The highest (R)-HPBA production was detected when 75 mM OPBA was used (Fig. 3B). The effect of the biocatalyst concentration was also investigated to determine the optimal range. The biotransformation was conducted with 75 mM OPBA, 75 mM sodium formate, 200 mM phosphate buffer (pH 6.5), and whole cells of E. coli DF at six different concentrations (1, 3, 5, 6, 7, and 8 g DCW l⁻¹). When the reactions were conducted to approximate 80% theoretical yield, the highest specific productivity was observed at a biocatalyst concentration of 6 g DCW l⁻¹ (Table 2).

Production of (R)-HPBA under optimal conditions

On the basis of the results presented above, an optimal biocatalysis system for production of optically pure (R)-HPBA from OPBA was developed. Biotransformation was conducted at 37°C in 200 mM phosphate buffer (pH 6.5) with 6 g DCW l⁻¹ whole cells of E. coli DF as the biocatalyst. As shown in Fig. 4A, 71.8 mM (R)-HPBA with a high enantiomeric purity (ee >99%), Fig. S2) was obtained from 73.4 mM OPBA in 90 min. When whole cells of E. coli D2 only expressing α-LDH/V294L/F296V were used as the biocatalyst, and glucose was added for NADH regeneration, only 44.7 mM (R)-HPBA was produced with a yield of 60.9% after 360 min (Fig. 4B).

Many biocatalysts have been used in the enantioselective production of (R)-HPBE and (R)-HPBA through bio-reduction [1,12,26–28]. Compared with (R)-HPBE production processes, the product concentrations of the reported (R)-HPBA synthesis processes were rather low (Table 3) [1,10–12,15,29,30]. In the previous study, purified α-LDH from Staphylococcus epidermidis and FDH from Candida boidinii were applied for (R)-HPBA production. (R)-HPBA at a concentration of 182 mM was produced, which is the highest reported yield of (R)-HPBA to date [15]. However, problems concerning the application of the process, such as the complicated enzyme purification and costly cofactor addition, remain. In the present work, mutant α-nLDH and FDH were co-expressed in E. coli DF and used for (R)-HPBA production from OPBA. The productivity (47.9 mM h⁻¹) and ee (>99%) of the product were rather high for (R)-HPBA production. Additionally, given the simple composition of the biocatalytic system, separation of (R)-HPBA from the biocatalytic system would be relatively inexpensive. Therefore, the novel process established in this study could also be used as a promising route for the production of highly optically pure (R)-HPBA.

Conclusions

In summary, whole cells of E. coli DF coexpressing α-LDH/V294L/F296V from L. bulgaricus ATCC 11842 and FDH from C. boidinii NCYC 1513 exhibited catalytic capability for (R)-HPBA production from OPBA. After optimization of the biotransformation conditions, 73.4 mM OPBA was reduced to 71.8 mM (R)-HPBA with a high productivity of 47.9 mM h⁻¹ and an excellent ee (>99%). The constructed coupled biocatalysis
system developed in this work may be a promising alternative for the production of the key medical intermediate (R)-HPBA.

Supporting Information

Figure S1  HPLC analysis of the product of the catalytic reaction by using whole cells of E. coli D2 (A) as the biocatalyst and glucose as the substrate for NADH regeneration or whole cells of E. coli DF (B) as the biocatalyst and sodium formate as the substrate for NADH regeneration. (TIF)

References

1. Yun H, Choi HL, Fadnavis NW, Kim BG (2005) Stereospecific synthesis of (R)-2-hydroxy carboxylic acids by recombinant E. coli BL21 overexpressing YiaE from Escherichia coli K12 and glucose dehydrogenase from Bacillus subtilis. Biotechnol Prog 21: 366–371.
2. de Lacera PSB, Ribeiro JB, Leite SFG, Coelho RB, Lima ELD, et al. (2006) Microbial enantioselective reduction of ethyl 2-oxo-3-phenylbutanoate. Biochem Eng J 29: 299–302.
3. de Lacera PSB, Ribeiro JB, Leite SFG, Ferrara MA, Coelho RB, et al. (2006) Microbial reduction of ethyl 2-oxo-1-phenylbutyrate. Searching for R-enantioselectivity. New access to the enantiolag like ACE inhibitors. Tetrahedron: Asymmetry 17: 1186–1189.
4. Chen B, Yin HF, Wang NS, Liu JY, Xu JH (2010) A new chemo-enzymatic route to chiral 2-hydroxy-4-phenylbutyrate by combining lactonase-mediated resolution with hydrogenation over Pt/C. Chem Commun 46: 2734–2736.
5. Huang Y, Liu N, Wu X, Chen Y (2010) Dihydrogenases/reductases for the synthesis of chiral pharmaceutical intermediates. Curr Org Chem 14: 1447–1460.
6. Iwasaki G, Kimura R, Numao N, Kondo K (1989) A practical and stable enzymatic resolution with hydrogenation over Pd/C. Chem Commun 46: 2754–2756.
7. Lin WQ, He Z, Jing Y, Cui X, Liu H, et al. (2001) A practical synthesis of ethyl 2-hydroxy-4-phenylbutyrate from 2-hydroxy-4-phenylbutyric acid–an intermediate of drug CIOC21. Adv Synth Catal 350: 426–430.
8. Larissegger-Schnell B, Glueck SM, Kroutil W, Faber K (2006) Enantio-complementary decarboxylation of (+/-)-2-hydroxy-4-phenylbutyric acid and (+/-)-3-phenylacetic acid using lipase-catalyzed kinetic resolution combined with biocatalytic racemization. Tetrahedron 62: 2912–2916.
9. Lin WQ, He Z, Jing Y, Cui X, Liu H, et al. (2001) A practical synthesis of ethyl (R)- and (S)-2-hydroxy-4-phenylbutanoate and its homophenylalanine ethyl ester hydrochloride from 2-malic acid. Tetrahedron: Asymmetry 12: 1583-1597.
10. Nakamura K, Yamanaka R, Matsuda T, Harada T (2005) Recent developments in asymmetric reduction of ketones with biocatalysts. Tetrahedron: Asymmetry 14: 2659–2681.
11. Larissegger-Schnell B, Glueck SM, Kroull W, Faber K (2006) Enantio-complementary decarboxylation of (+/-)-2-hydroxy-4-phenylbutyric acid and (+/-)-3-phenylacetic acid using lipase-catalyzed kinetic resolution combined with biocatalytic racemization. Tetrahedron 62: 2912–2916.
12. Shen ND, Ni Y, Ma HM, Wang LJ, Li CX, et al. (2012) Efficient synthesis of a chiral precursor for angiotensin converting enzyme (ACE) inhibitors in high space-time yield by a new reductase without external cofactors. Org Lett 14: 1992–1995.
13. Ni Y, Su Y, Li H, Zhou J, Sun Z (2013) Scalable biocatalytic synthesis of optically pure ethyl (R)-2-hydroxy-4-phenylbutyrate using a recombinant E. coli with high catalytic yield. J Biotechnol 168: 493–498.
14. Bai Y, Yang ST (2007) Production and separation of formate dehydrogenase. Bioresour Technol 98: 249–253.
15. Kalaritis P, Regenye RW, Partridge JJ, Coffen DL (1990) Kinetic resolution of 2-substituted esters catalyzed by a lipase ex. Pseudomonas fluorescens. J Org Chem 55: 812–815.
16. Zheng Z, Sheng B, Gao C, Zhang H, Qin T, et al. (2013) Highly stereoselective biosynthesis of (R)-2-hydroxy carboxylic acids through rationally re-designed mutation of α-lactate dehydrogenase. Sci Rep 3: 3401.
17. Schmidt E, Ghisalba O, Gygy D, Sedelmair G (1992) Optimization of a process for the production of (R)-2-hydroxy-4-phenylbutyric acid–an intermediate for inhibitors of angiotensin converting enzyme. J Biotechnol 24: 315–327.
18. Zheng Z, Ma C, Gao C, Li F, Qin J, et al. (2011) Efficient conversion of phenylpyruvic acid to phenylactic acid by using whole cells of Bacillus coagulans SDM. PLoS One 6: e19030.
19. Gao C, Zhang X, Lu Y, Hu C, Zhang Y, et al. (2013) Production of (S)-acetoin from diacetyl by using stereoselective NADPH-dependent carbonyl reducctase and glucose dehydrogenase. Bioresour Technol 137: 111–115.
20. Markwell MAK, Haas SM, Bieber LL, Tolbert NE (1976) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 67: 206–210.
21. Bai Y, Yang ST (2007) Production and separation of formate dehydrogenase from Candida boidinii. Enzyme Microb Technol 40: 946–949.
22. Schütte H, Flossdorf J, Salm H, Kula M-R (1976) Purification and properties of formaldehyde dehydrogenase and formate dehydrogenase from Candida boidinii. Eur J Biochem 62: 151–160.
23. Wang Y, Li L, Ma G, Gao C, Tao F, et al. (2013) Engineering of cofactor regeneration enhances (2S,3S)-2-butanol production from diacetyl. Sci Rep 3: 2643.
24. Frohlich P, Albert K, BERTAU M (2011) Formate dehydrogenase – a biocatalyst with novel applications in organic chemistry. Org Biomol Chem 9: 7941–7950.
25. Yu S, Zhu L, Zhou C, An T, Jiang B, et al. (2013) Enzymatic production of (S)-phenylactic acid by Pediococcus pentosaceus α-lactate dehydrogenase with NADH regeneration by Oligotropha parae留意rophora formate dehydrogenase. Biotechnol Lett 36:627–631.
26. Zhang W, Ni Y, Sun Z, Zheng P, Lin W, et al. (2009) Biocatalytic synthesis of ethyl (R)-2-hydroxy-4-phenylbutyrate with Candida lusitana SW2602. A practical approach for high enantio-purity and product titer. Process Biochem 44: 1270–1275.
27. Chen Y, Lin H, Xu X, Xia S, Wang L (2008) Preparation the key intermediate of angiotensin-converting enzyme (ACE) inhibitors: High enantioselective production of ethyl (R)-2-hydroxy-4-phenylbutyrate with Candida boudin CI0231. Adv Synth Catal 350: 426–430.
28. He CM, Chang DL, Zhang J (2008) Asymmetric reduction of substituted α- and β-ketoesters by Bacillus firmus Phc-C3. Tetrahedron: Asymmetry 19: 1347–1351.
29. Shi Y, Fang Y, Ren Y, Guan H, Zhang JY (2009) Applying alpha-phenacyl chloride to the enantioselective reduction of ethyl 2-oxo-1-phenylbutyrate with baker’s yeast. J Chem Technol Biotechnol 84: 661–668.
30. Shi YG, Fang Y, Wu HP, Li F, Zhao XQ (2009) Improved production of ethyl (R)-2-hydroxy-4-phenylbutyrate with pretreated Sarcosomycetes cerevisiae in water/organic solvent two-liquid phase systems. Biocatal Biotransform 27: 211–219.
31. Su Y, Ni Y, Wang J, Xu Z, Sun Z (2012) Two-enzyme coexpressed recombinant strain for asymmetric synthesis of ethyl (R)-2-hydroxy-4-phenylbutyrate. Chin J Catal 33: 1650–1660.

Figure S2  HPLC analysis of the product of the catalytic reaction utilizing the whole cell biocatalyst. (A) HPLC analysis of (R)-HPBA and (S)-HPBA. (B) Product of the catalytic reaction. (TIF)

Author Contributions

Conceived and designed the experiments: BS CG CM PX. Performed the experiments: BS ML HZ TQ. Analyzed the data: BS ZZ CG CM. Contributed reagents/materials/analysis tools: CG CM PX. Wrote the paper: BS CG CM PX.